Duurland, CL;
Wedderburn, LR;
(2014)
Current developments in the use of biomarkers for juvenile idiopathic arthritis.
Current Rheumatology Reports
, 16
, Article 406. 10.1007/s11926-013-0406-3.
Preview |
Text
Wedderburn_art%253A10.1007%252Fs11926-013-0406-3.pdf Download (191kB) | Preview |
Abstract
Use of biomarkers in clinical practice has proved extremely valuable and is a rapidly expanding field. However, despite the huge potential of biomarkers, for juvenile idiopathic arthritis (JIA) there are currently no validated paediatric biomarkers available to help with setting up a more tailored approach on which drug choice could be based, to achieve remission early in the course of disease. Early remission reduces burden of disease, limits side effects from toxic and unnecessary medication, and, most importantly, enhances quality of life. Several studies have suggested promising biomarkers: these may be a protein, cellular component, mRNA, or genetic component, for example a single nucleotide polymorphism (SNP). Here we describe recent developments in the use of biomarkers for JIA and their potential to assist in management of disease by predicting disease phenotype, severity, progression, and response to treatment, and determining when patients have reached stable remission and can safely discontinue treatment.
| Type: | Article |
|---|---|
| Title: | Current developments in the use of biomarkers for juvenile idiopathic arthritis |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s11926-013-0406-3 |
| Publisher version: | http://dx.doi.org/10.1007/s11926-013-0406-3 |
| Language: | English |
| Additional information: | Copyright © The Author(s) 2014. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
| Keywords: | Antirheumatic Agents, Arthritis, Juvenile, Biological Markers, Disease Progression, Humans, Phenotype, Prognosis, Remission Induction, Biomarker, JIA, Juvenile idiopathic arthritis, CRP, ESR, S100, MRP, SNP, MTX, Methotrexate Treatment Remission |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1420643 |
Archive Staff Only
 |
View Item |
